Related Experiment Video
Updated: Aug 18, 2026
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
[Efficacy of rifampicin in experimental plague infection]
Abstract:
The effect of rifampicin on the plague microbe was studied in vitro and in albino mice with experimental plague infection. The rifampicin MIC with respect to 50 strains of the plague microbe of different origin in the tests on the Hottinger agar ranged from 1.6 to 6.4 micrograms/ml. High efficacy of rifampicin was shown in the prophylaxis and treatment of experimental plague when used in doses of 25 and 50 mg/kg once every 24 hours for 5 to 7 days. Rifampicin prevented the development of plague in at least 80 per cent of the albino mice when it was administered 1, 3, 6 and 24 hours prior to the infection. The antibiotic had a prolonged action and preserved its high efficacy after the administration at intervals of 48 and 72 hours.
Insights
Rifampicin effectively combats the plague microbe, demonstrating high efficacy in preventing and treating experimental plague infections in mice. This antibiotic shows prolonged action and maintains effectiveness even when administered hours before or after infection.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Plague remains a significant public health concern.
- The plague microbe (Yersinia pestis) requires effective antimicrobial treatments.
- Understanding antibiotic efficacy is crucial for plague management.
Purpose of the Study:
- To evaluate the in vitro and in vivo efficacy of rifampicin against the plague microbe.
- To determine the minimum inhibitory concentration (MIC) of rifampicin for various plague microbe strains.
- To assess rifampicin's effectiveness in prophylaxis and treatment of experimental plague infections.
Main Methods:
- In vitro susceptibility testing of 50 plague microbe strains to rifampicin.
- Determination of rifampicin's Minimum Inhibitory Concentration (MIC) using Hottinger agar.
- Experimental plague infection model in albino mice to evaluate prophylactic and therapeutic effects of rifampicin.
- Administration of rifampicin at various dosages and time points relative to infection.
Main Results:
- Rifampicin MIC ranged from 1.6 to 6.4 µg/ml for 50 plague microbe strains.
- High efficacy observed in prophylaxis and treatment at 25 and 50 mg/kg doses.
- Rifampicin prevented plague in over 80% of mice when given up to 24 hours pre-infection.
- The antibiotic demonstrated prolonged action and sustained efficacy at 48 and 72 hours post-administration.
Conclusions:
- Rifampicin is a potent antimicrobial agent against the plague microbe.
- The drug exhibits significant prophylactic and therapeutic potential in experimental plague.
- Rifampicin's prolonged action supports its use in plague management strategies.
More Related Videos
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
07:28Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:24Plague